Adverse events associated with immune checkpoint inhibitor treatment for cancer

CMAJ. 2019 Jan 14;191(2):E40-E46. doi: 10.1503/cmaj.180870.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / immunology
  • Antineoplastic Agents, Immunological / therapeutic use
  • CTLA-4 Antigen / antagonists & inhibitors*
  • CTLA-4 Antigen / immunology
  • Cell Cycle Checkpoints / drug effects
  • Cell Cycle Checkpoints / immunology
  • Humans
  • Immune System Diseases / chemically induced*
  • Immune System Diseases / drug therapy
  • Immune System Diseases / therapy
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology

Substances

  • Antineoplastic Agents, Immunological
  • CTLA-4 Antigen
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor